Literature DB >> 18000163

Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells.

Amélie Guihot1, Eric Oksenhendler, Lionel Galicier, Anne-Geneviève Marcelin, Laura Papagno, Anne-Sophie Bedin, Félix Agbalika, Nicolas Dupin, Jacques Cadranel, Brigitte Autran, Guislaine Carcelain.   

Abstract

Multicentric Castleman disease (MCD) is a devastating human herpesvirus 8 (HHV-8)-related lymphoproliferative disorder that occurs in immunocompromised persons. To determine the role of immune responses in MCD, we studied the frequency, antigenic repertoire, differentiation, and functional profile of HHV-8-specific CD8(+) T cells in MCD patients and in human immunodeficiency virus-coinfected asymptomatic HHV-8 carriers (AC). Screening CD8(+) T-cell responses with ELISpot interferon-gamma (IFN-gamma) assays using 56 peptides on 6 latent and lytic HHV-8 proteins showed that MCD and AC patients had responses of similar magnitude and antigenic repertoire and identified a new 10-mer human leukocyte antigen B7 CD8 epitope in K15. Intracellular IFN-gamma staining showed significantly more CD45RA(-)CCR7(-)CD27(-) CD8(+)IFN-gamma(+) cells (late phenotype) and significantly fewer CCR7(-)CD27(+)CD45RA(-) cells (early and intermediate phenotype) in MCD than in AC patients. This phenotypic shift was not found for Epstein-Barr virus-specific CD8(+) T cells tested as controls. HHV-8 viral loads were negatively correlated with early and intermediate effector memory cells. HHV-8-specific T cells were polyfunctional (secretion of IFN-gamma, tumor necrosis factor-alpha, macrophage inflammatory protein-1beta, and/or CD107a) in both MCD and AC patients. In conclusion, MCD is not associated with a lack of HHV-8-specific CD8(+) T cells or limitation of their functional profile. Their differentiation increases with HHV-8 viral load. These results offer new insight into the pathophysiology of MCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000163     DOI: 10.1182/blood-2007-03-080648

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Authors:  Paolo Nicoli; Ubaldo Familiari; Marco Bosa; Tiziano Allice; Francesca Mete; Alessandro Morotti; Daniela Cilloni; Giuseppe Saglio; Angelo Guerrasio
Journal:  Int J Hematol       Date:  2009-09-12       Impact factor: 2.490

2.  iNKT cell defects in HHV-8-associated MCD.

Authors:  Thomas S Uldrick
Journal:  Blood       Date:  2017-02-16       Impact factor: 22.113

3.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

Review 4.  Castleman's disease--a two compartment model of HHV8 infection.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Clin Oncol       Date:  2010-07-06       Impact factor: 66.675

5.  Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice.

Authors:  Gianna Ballon; Kang Chen; Rocio Perez; Wayne Tam; Ethel Cesarman
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

6.  Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.

Authors:  Lauren Lepone; Giovanna Rappocciolo; Emilee Knowlton; Mariel Jais; Paolo Piazza; Frank J Jenkins; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

7.  Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Authors:  Jianmin Zuo; Andrew D Hislop; Carol S Leung; Shereen Sabbah; Martin Rowe
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 8.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.

Authors:  Kathryn Lurain; Robert Yarchoan; Thomas S Uldrick
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

9.  Professional antigen presenting cells in human herpesvirus 8 infection.

Authors:  Emilee R Knowlton; Lauren M Lepone; Jun Li; Giovanna Rappocciolo; Frank J Jenkins; Charles R Rinaldo
Journal:  Front Immunol       Date:  2013-01-21       Impact factor: 7.561

10.  The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Rebecca C Robey; Salvinia Mletzko; Frances M Gotch
Journal:  Adv Virol       Date:  2011-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.